Harvard Bioscience (HBIO) Set to Release Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is expected to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $21.80 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%. The business had revenue of $22.73 million for the quarter, compared to analyst estimates of $21.45 million.

Harvard Bioscience Stock Up 2.0%

Harvard Bioscience stock traded up $0.17 during mid-day trading on Tuesday, reaching $8.78. The stock had a trading volume of 1,408 shares, compared to its average volume of 33,062. The company has a debt-to-equity ratio of 4.94, a quick ratio of 0.98 and a current ratio of 1.87. Harvard Bioscience has a fifty-two week low of $4.00 and a fifty-two week high of $9.10. The stock’s 50-day simple moving average is $8.14 and its 200-day simple moving average is $6.45. The firm has a market capitalization of $39.93 million, a PE ratio of -3.80 and a beta of 1.50.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HBIO. Benchmark upped their target price on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. Weiss Ratings downgraded shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.75.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.